Home Journals Articles Updates About
CN
image
收藏切换
Comprehensive profiling and evaluation of the alteration of RNA modifications in thyroid carcinoma by liquid chromatography-tandem mass spectrometry
收藏切换
PDF
Meng-Yuan Chena, b, 1, Chu-Bo Qic, 1, Xiao-Meng Tanga, b, Jiang-Hui Dinga, b, Bi-Feng Yuan*, a, b, Yu-Qi Fenga, b
Chinese Chemical Letters | 2022, 33(8) : 3772 - 3776
Less
收藏切换
Chinese Chemical Letters | 2022, 33(8): 3772-3776
• Communication •
Comprehensive profiling and evaluation of the alteration of RNA modifications in thyroid carcinoma by liquid chromatography-tandem mass spectrometry
Full
Meng-Yuan Chena, b, 1, Chu-Bo Qic, 1, Xiao-Meng Tanga, b, Jiang-Hui Dinga, b, Bi-Feng Yuan*, a, b, Yu-Qi Fenga, b
Affiliations
  • aSchool of Public Health, Wuhan University, Wuhan 430071, China
  • bDepartment of Chemistry, Sauvage Center for Molecular Sciences, Wuhan University, Wuhan 430072, China
  • cJiangxi Provincial People's Hospital Affiliated to Nanchang University, Nanchang 330006, China
Published: 2022-08-15 doi: 10.1016/j.cclet.2021.12.008
Outline
收藏切换

RNA molecules contain diverse modifications that display important functions in a variety of physiological and pathological processes. So far over 150 chemical modifications have been characterized to be present in various RNA species, such as in messenger RNA (mRNA), ribosomal RNA (rRNA), and transfer RNA (tRNA). Previous studies revealed that certain RNA modifications were correlated to specific human diseases, indicating RNA modifications could serve as the potential indicator of human diseases. However, systemic investigation of the alteration of RNA modifications in different RNA species of carcinoma tissues are still lacked. Herein, we carried out the comprehensive profiling and evaluation of the alteration of RNA modifications in thyroid carcinoma by liquid chromatography-tandem mass spectrometry (LC-ESI-MS/MS) analysis. The developed method allowed us to simultaneously detect 48 different types of RNA modifications. Using this method, we detected 10, 15, 14, and 25 modifications in mRNA, 18S rRNA, 28S rRNA and small RNA (< 200 nt), respectively. Compared to the normal tissues, we revealed a total of 14 RNA modification exhibited significant increase and 2 RNA modifications showed significant decrease in thyroid carcinoma tissues. Our study provided the first comprehensive profile as well as the alteration of modifications in different RNA species in thyroid carcinoma and matched tumor-adjacent normal tissues. The altered pattern RNA modifications may serve as the indicator of thyroid carcinoma. Moreover, this study may promote the in-depth understanding of the regulatory roles of RNA modifications in thyroid carcinoma.

RNA modification  /  Liquid chromatography-mass spectrometry  /  Thyroid carcinoma  /  Profiling
Meng-Yuan Chen, Chu-Bo Qi, Xiao-Meng Tang, Jiang-Hui Ding, Bi-Feng Yuan, Yu-Qi Feng. Comprehensive profiling and evaluation of the alteration of RNA modifications in thyroid carcinoma by liquid chromatography-tandem mass spectrometry[J]. Chinese Chemical Letters, 2022 , 33 (8) : 3772 -3776 . DOI: 10.1016/j.cclet.2021.12.008
Full Text
Less
DNA cytosine methylation is a well-explored epigenetic modification that can regulate gene expression in mammals [1-5]. Apart from DNA, RNA molecules also contain numbers of chemical modifications [6]. Mirroring DNA epigenetics, RNA epigenetics is an emerging field and over 150 structurally distinct modifications have been identified in different RNA species, including messenger RNA (mRNA), ribosomal RNA (rRNA), and transfer RNA (tRNA) [6, 7]. The nucleobases as well as the ribose of RNA can be chemically modified to form diverse modifications, such as 5-methylcytidine (m5C), N6-methyladenosine (m6A), 2′-O-methylation, N1-methyladenosine (m1A), N6, 2′-O-dimethyladenosine (m6Am), N7-methylguanosine (m7G), N3-methylcytidine (m3C), and N4-acetylcytidine (ac4C) [8-13].
The modifications in RNA greatly diversify their functions. Many RNA modifications are reversible and they play critical roles in modulating both physiological and pathological processes [14, 15]. The recognition factors of modifications can delicately control and regulate RNA stability, folding, localization and maturation. Although the complete functional roles of RNA modifications have not been fully unveiled, the known physiological functions of RNA modifications have been demonstrated to be involved in carcinogenesis, adipogenesis, spermatogenesis, and cell differentiation [16, 17].
Due to the vital roles of RNA modifications in regulating cell fate decision, the dysregulation of RNA modifications, in terms of their levels and distributions, may contribute to carcinogenesis. In fact, the accumulated lines of evidence have established the links between specific RNA modifications and cancer onset and evolution [18]. Several RNA modifications have been characterized for their effects on promoting cancer cell proliferation or invasiveness [19]. For example, the level of pseudouridine (Y) is increased in malignant prostate compared to normal tissue [20]. N6, 2′-O-dimethyladenosine (m6Am) can promote chemoresistance in colorectal cancer cells [21]. A few studies have shown that RNA modification pathways can regulate cell metabolism; conversely, cancer-specific metabolic changes have the potential to affect RNA modifications [22]. These studies highlight the importance of RNA modification pathways in tumorigenesis.
Considering we are in the early stage of RNA epigenetics, the effects of RNA modifications on cancer hallmark are still poorly understood. Nevertheless, deciphering the alteration of the levels of RNA modification from carcinoma tissues and normal tissues should provide valuable information for in-depth understanding of carcinogenesis as well as for disease diagnosis. Thyroid carcinoma is one of the most prevalent human malignancies [23]. However, there are few studies investigating the correlation of RNA modifications in different RNA species with thyroid carcinoma. In this respect, herein we systematically carried out the comprehensive profiling and evaluation of the alteration of RNA modifications in different RNA species of thyroid carcinoma and matched tumor-adjacent normal tissues by liquid chromatography-tandem mass spectrometry (LC-ESI-MS/MS) analysis (Fig. 1).
A LC-ESI-MS/MS method to simultaneously detect 48 RNA modifications was first established (Fig. 2, Fig. S1 and Table S1 in Supporting information). Among these modifications, there are eight groups of isomeric RNA modifications (m1A and m6A; io6A (cis) and io6A (trans); m1G, m2G, and m7G; m3C and m5C; f5C and m4, 4C; s2U, s4U and ho5U; m3U and m5U; mo5U and m5s2U) and eight groups of RNA modifications with similar molecular weights (m1A, m6A and m1I; Am and Im; Cm and Um; m3C, m5C, m3U and m5U; m3U, m5U and s2C; s2C, ho5U, s2U and s4U; hm5C, mo5U and m5s2U; m5Cm and m5Um). Under the LC-ESI-MS/MS analysis with multiple reaction monitoring (MRM) detection mode, RNA modifications with same or similar MRM mass transitions need to be efficiently separated for their identification. Thus, we optimized the chromatographic separation conditions for these 48 RNA modifications. Under the optimal conditions, all these 48 RNA modifications, especially those with same or similar molecular weights, were well distinguished from each other (Fig. 2 and Table S2 in Supporting information), which allowed the simultaneous detection and quantification of 48 RNA modifications.
The optimized LC-ESI-MS/MS method was then applied to detect and quantify RNA modifications from different RNA species of thyroid tissues, including mRNA, 18S rRNA, 28S rRNA and small RNA (< 200 nt). mRNA, small RNA (< 200 nt) and large RNA (> 200 nt) were extracted using the commercial kit according to previous report [24, 25] and the extraction procedure of mRNA could be found in Supporting information (Fig. S2 in Supporting information). The 18S rRNA and 28S rRNA were isolated from the large RNA (> 200 nt) by size-exclusion chromatography according to the previous reports [26, 27] (Fig. S3 in Supporting information). The LC-ESI-MS/MS results showed that 10, 15, 14, and 25 kinds of RNA modifications could be detected in mRNA (Fig. 3), 18S rRNA (Figs. S4 and S5 in Supporting information), 28S rRNA (Figs. S6 and S7 in Supporting information) and small RNA (< 200 nt) (Figs. S8–S11 in Supporting information), respectively. The retention times of these detected RNA modifications from different RNA species were identical to those of their standards (Fig. 3 and Figs. S4–S11). It is remarkable that all these detected modifications were not detectable in the enzyme control samples (Figs. 3 and Figs. S4–S11), validating that these detected RNA modifications were from RNA samples.
We next evaluated the abundance of RNA modifications in thyroid carcinoma and matched tumor-adjacent normal tissues. Thus, the calibration curves were first constructed to quantify RNA modifications. A series of mixed solutions that contain different amounts of RNA modifications and a certain amount of isotopic internal standard (rC-13C5) were prepared. We constructed calibration curves by plotting peak area ratios of nucleosides/rC-13C5 against the amounts of nucleosides. The good linearities were achieved with the coefficients of determination (R2) being greater than 0.99 (Table S3 in Supporting information). The limits of detection (LODs) and the limits of quantification (LOQs), which are defined as the amounts of analytes at signal-to-noise ratio of 3 and 10, respectively, were used to evaluate the detection sensitivities for RNA modifications by the established method [28]. LODs of RNA modifications ranged from 0.05 fmol to 486.3 fmol and LOQs were between 0.18 fmol and 1621.01 fmol (Table S3). The precision and accuracy for RNA modifications quantification were evaluated through calculating intra- and inter-day relative standard deviations (RSDs) and relative errors (REs), which were less than 17.4% and 17.6%, respectively (Table S4 in Supporting information). These results manifested the acceptable precision and accuracy for quantification of RNA modifications.
With the validated LC-ESI-MS/MS method, we then quantified RNA modifications in mRNA, 18S rRNA, 28S rRNA and small RNA (< 200 nt) of thyroid carcinoma and the matched tumor-adjacent normal tissues (Table S5 in Supporting information). The results showed that the measured contents of various RNA modifications were from 0.00010% to 11.26% in different RNA species, indicating the large content ranges of endogenous RNA modifications. Nevertheless, the current developed method showed good capability in the simultaneous quantification of these RNA modifications. In addition, the measured levels of these modifications were comparable to the previously reported levels in RNA of mammals (Tables S6–S9 in Supporting information). As for the detectable 10 RNA modifications (m1A, m6A, m6Am, Am, m7G, Gm, m3C, m5C, Cm and I) from mRNA, the level of m5C showed significant increase in thyroid carcinoma compared to the matched tumor-adjacent normal tissues (Fig. 4a). In our previous study, we also observed the increased levels of m5C in RNA in circulating tumor cells of patients with lung cancer [29]. These results indicated that m5C in mRNA may have important role on thyroid carcinoma.
As for 18S rRNA, 14 RNA modifications (m1A, m6A, m6, 6A, Am, m7G, m1G, m2, 2G, Gm, m5C, ac4C, Cm, m3U, Um and Y) could be quantified except m2G (Fig. 4b). Although m2G was detectable in both 18S rRNA and 28S rRNA (Figs. S4 and S6 in Supporting information), it was not quantified in all the analyzed tissues due to its relatively low abundance. Thus, m2G was not included in the quantification data for 18S rRNA and 28S rRNA. The quantification results illustrated that m2, 2G and m1G in 18S rRNA exhibited significant increase in thyroid carcinoma compared to the matched tumor-adjacent normal tissues. As for 28S rRNA, 13 RNA modifications (m1A, m6A, m6, 6A, Am, m7G, m1G, m2, 2G, Gm, m5C, Cm, m3U, Um and Y) could be quantified (Fig. 4c). Among these modifications, m2, 2G, m1G, and m7G showed significantly higher levels in thyroid carcinoma compared to the matched tumor-adjacent normal tissues. In addition, we also observed the significant decline of Um in 28S rRNA of thyroid carcinoma. It is worth noting that m2, 2G and m1G showed significant increase in both 18S rRNA and 28S rRNA, indicating that these two RNA modifications in 18S rRNA and 28S rRNA should have important impact on thyroid carcinoma development.
Since the greatest number of modifications (25 RNA modifications) were detected in small RNA (< 200 nt) (Fig. 4d), we found 14 modifications (m5Cm, mcm5U, m1I, mcm5s2U, ac4C, m5Um, m7G, I, t6A, m5U, m2, 2G, m5C, m1G and m2G) exhibited significant increase in thyroid carcinoma compared to the normal tissues (Fig. 4d). Moreover, we observed the level of Am was significantly decreased in small RNA (< 200 nt) of thyroid carcinoma tissues (Fig. 4d).
The quantification results demonstrated an overall increased trend of RNA modifications in thyroid carcinoma compared to the matched tumor-adjacent normal tissues. As previous studies also demonstrated the increased levels of some RNA modifications in the tissues of cancer patients. For example, there are studies reporting that m6A in total RNA of gastric cancer tissues and m6A in mRNA of human hepatocellular carcinoma tissues was increased compared to the controls [30, 31]. The levels of m5Cm in total RNA of human lung carcinoma tissues and m5C in mRNA of urothelial carcinoma tissues showed increasing trends compared to the matched normal tissues 32-34]. Our results, together with these previous studies, revealed that aberrant levels of RNA modifications were closely correlated to certain human diseases, which lays a foundation for diagnosis, monitoring disease evolution, and predicting response to treatment through specific RNA modification patterns.
We revealed that totally 16 RNA modifications exhibited significant difference (14 modifications increase and 2 modifications decrease) between thyroid carcinoma and matched tumor-adjacent normal tissues. Although the precise underlying mechanisms that explain how RNA modifications link to tumorigenesis remain unknown, we reason that the differentiated levels of RNA modifications may derive from the aberrant expression of RNA modifying enzymes. The contributions of these modifying enzymes and respective modification to tumor initiation, growth, and metastasis need to be further investigated in future study.
In summary, here we established the LC-ESI-MS/MS method for the simultaneous detection of 48 different types of RNA modifications. With the developed method, we carried out the comprehensive profiling and evaluation of the alteration of RNA modifications in thyroid carcinoma. We detected 10, 15, 14, and 25 modifications in mRNA, 18S rRNA, 28S rRNA and small RNA (< 200 nt), respectively. Compared to the normal tissues, the quantification data showed a total of 14 RNA modifications exhibited significant increase and 2 RNA modifications showed significant decrease in thyroid carcinoma tissues. The specific pattern RNA modifications offer the new strategy for the diagnosis of thyroid cancer. Future investigation on the underlying mechanisms of the alteration of RNA modifications may also provide new opportunity on the thyroid carcinoma treatment through targeting RNA modifications and RNA modifying enzymes.
Declaration of competing interest
Less
The authors declare no competing financial interests.
Acknowledgments
Less
The work is supported by the National Natural Science Foundation of China (No. 22074110), and the Fundamental Research Funds for the Central Universities (No. 2042021kf0212).
Supplementary materials
Less
Supplementary material associated with this article can be found, in the online version, at doi:10.1016/j.cclet.2021.12.008
References
Less
[1]
C. Luo, P. Hajkova, J.R. Ecker, Science 361 (2018) 1336–1340.
[2]
T. Liu, C.J. Ma, B.F. Yuan, Y.Q. Feng, Sci. China Chem. 61 (2018) 381–392.
[3]
Y. Feng, N.B. Xie, W.B. Tao, et al., CCS Chem. 2 (2020) 994–1008.
[4]
B.F. Yuan, Chem. Res. Toxicol. 33 (2020) 695–708.
[5]
Y. Feng, J.J. Chen, N.B. Xie, et al., Chem. Sci. 12 (2021) 11322–11329.
[6]
P. Boccaletto, M.A. Machnicka, E. Purta, et al., Nucleic Acids Res. 46 (2018) D303–D307.
[7]
Q. Wang, J.H. Ding, J. Xiong, et al., Chin. Chem. Lett. 32 (2021) 3426–3430.
[8]
B.S. Zhao, I.A. Roundtree, C. He, Nat. Rev. Mol. Cell Biol. 18 (2017) 31–42.
[9]
M.D. Lan, B.F. Yuan, Y.Q. Feng, Chin. Chem. Lett. 30 (2019) 1–6.
[10]
C.B. Qi, H.P. Jiang, J. Xiong, B.F. Yuan, Y.Q. Feng, Chin. Chem. Lett. 30 (2019) 553–557.
[11]
D. Wiener, S. Schwartz, Nat. Rev. Genet. 22 (2021) 119–131.
[12]
P.J. McCown, A. Ruszkowska, C.N. Kunkler, et al., Wiley Interdiscip. Rev. RNA 11 (2020) e1595.
[13]
C.B. Qi, J.H. Ding, B.F. Yuan, Y.Q. Feng, Chin. Chem. Lett. 30 (2019) 1618–1626.
[14]
I.A. Roundtree, M.E. Evans, T. Pan, C. He, Cell 169 (2017) 1187–1200.
[15]
K. Chen, B.S. Zhao, C. He, Cell Chem. Biol. 23 (2016) 74–85.
[16]
S. Delaunay, M. Frye, Nat. Cell Biol. 21 (2019) 552–559.
[17]
M.B. Uddin, Z. Wang, C. Yang, Theranostics 10 (2020) 3164–3189.
[18]
I. Barbieri, T. Kouzarides, Nat. Rev. Cancer 20 (2020) 303–322.
[19]
R. Thapar, A. Bacolla, C. Oyeniran, et al., Biochemistry 58 (2019) 312–329.
[20]
J.A. Stockert, A. Gupta, B. Herzog, et al., Am. J. Clin. Exp. Urol. 7 (2019) 262–272.
[21]
S. Relier, J. Ripoll, H. Guillorit, et al., Nat. Commun. 12 (2021) 1716.
[22]
H.L. Huang, H.Y. Weng, X.L. Deng, J.J. Chen, Annu. Rev. Cancer Biol. 4 (2020) 221–240.
[23]
M. Yarchoan, V.A. LiVolsi, M.S. Brose, J. Clin. Oncol. 33 (2014) 7–8.
[24]
Y. Dai, C.B. Qi, Y. Feng, et al., Anal. Chem. 93 (2021) 6938–6946.
[25]
M.Y. Cheng, X.J. You, J.H. Ding, et al., Chem. Sci. 12 (2021) 8149–8156.
[26]
M.D. Lan, J. Xiong, X.J. You, et al., Chem. Eur. J. 24 (2018) 9949–9956.
[27]
Q.Y. Cheng, J. Xiong, C.J. Ma, et al., Chem. Sci. 11 (2020) 1878–1891.
[28]
A. Kruve, R. Rebane, K. Kipper, et al., Anal. Chim. Acta 870 (2015) 29–44.
[29]
W. Huang, C.B. Qi, S.W. Lv, et al., Anal. Chem. 88 (2016) 1378–1384.
[30]
T. Liu, S. Yang, J. Sui, et al., J. Cell. Physiol. 235 (2020) 548–562.
[31]
M. Chen, L. Wei, C.T. Law, et al., Hepatology 67 (2018) 2254–2270.
[32]
Y. Feng, C.J. Ma, J.H. Ding, et al., Anal. Chim. Acta 1098 (2020) 56–65.
[33]
X. Chen, A. Li, B.F. Sun, et al., Nat. Cell Biol. 21 (2019) 978–990.
[34]
X.J. You, T. Liu, C.J. Ma, et al., Anal. Chem. 91 (2019) 10477–10483.
Appendix
Less
Year 2022 volume 33 Issue 8
PDF
52
29
Cite this Article
BibTeX
Article Info
doi: 10.1016/j.cclet.2021.12.008
  • Receive Date：2021-09-18
  • Online Date：2025-12-19
  • Published：2022-08-15
Article Data
Affiliations
History
  • Received：2021-09-18
  • Revised：2021-11-08
  • Accepted：2021-12-06
Affiliations
    aSchool of Public Health, Wuhan University, Wuhan 430071, China
    bDepartment of Chemistry, Sauvage Center for Molecular Sciences, Wuhan University, Wuhan 430072, China
    cJiangxi Provincial People's Hospital Affiliated to Nanchang University, Nanchang 330006, China
References
Share
https://castjournals.cast.org.cn/joweb/ccl/EN/10.1016/j.cclet.2021.12.008
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family		 属数
Number of
genus		 种数
Number of
species		 占总种数比例
Percentage of
total species (%)		 属
Genus		 种数
Number of
species		 占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT
Links
Articles
Latest Articles
Most Read
Collections
Updates
Events
News
Multimedia
About
About Us
Contact
No. 86 Xueyuan South Road, Haidian District, Beijing
100081
010-62199257
qkjq@cast.org.cn

Copyright © 2025 China Association for Science and Technology. All rights reserved. For all open access content, the relevant licensing terms apply.
Sponsored by the Office of the Leading Group for Cybersecurity and Informatization of CAST, and supported by Science and Technology Review Publishing House